Solna

• KANDOVA An open multicenter study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determ … Ended
  2024-515572-13-00 9 2023-04-26 Recurrent epithelial ovarian, fallopian tube, or primary peritoneal ca
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended
  2022-501538-44-00 5 2023-04-25 Atopic Dermatitis
• A superiority study to compare the effect of Panzyga versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome Ended
  2024-511673-30-00 5 2023-03-20 Pediatric acute-onset neuropsychiatric syndrome (PANS)
• C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended
  2024-513269-37-00 6 2023-03-14 Migraine attacks with or without aura
• C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan … Ended
  2024-513270-21-00 6 2023-03-14 migraine headaches with or without aura
• A study to evaluate the efficacy and safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 Ended
  2023-504540-33-00 5 2023-03-06 COVID-19
• Safety and Tolerability of AC01 in patients with heart failure Ended
  2022-500347-20-00 9 2023-02-23 Heart Failure
• Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer Ended
  2022-500808-21-00 4 2023-02-01 Metastatic triple negative breast cancer
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors Ended
  2022-500094-14-00 1 2022-11-08 gastroesophageal junction [GEJ] carcinoma
• A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Ended
  2024-510729-24-00 6 2022-09-01 Chronic Migrane, Migrane, Medication Overuse Headache
• A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorect … Ended
  2023-503797-21-00 5 2022-08-10 Metastatic Colorectal Cancer
• Phase 3, Placebo-Controlled, Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Trial of a 6-Valent OspA-Based Lyme Disease … Ended
  2023-509105-72-00 5 2022-08-10 Active immunization against Lyme disease
• Brightline-1: A study to compare brigimadlin (BI 907828) with doxorubicin in people with a type of cancer called dedifferentiated liposarcom … Ended
  2024-511361-11-00 10 2022-03-25 Advanced dedifferentiated liposarcoma
• A study to evaluate ExPEC9V vaccine for the prevention of Invasive E. coli Disease in adults aged 60 years and older with a history of urina … Ended
  2023-506589-30-00 5 2022-02-09 Invasive Extraintestinal Pathogenic Escherichia coli Disease
• A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectivenes … Ended
  2022-501243-33-00 4 2022-02-03 Diffuse Large B Cell Lymphoma (a type of non-Hodgkin’s lymphoma, in pa
• Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III … Ended
  2023-507688-20-00 5 2021-12-03 Participants with completely resected Stage III or Stage IV melanoma
• A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended
  2022-500881-80-00 5 2021-10-29 Chronic Heart Failure With Reduced Ejection Fraction
• First-in-Human Study of RLY-4008 in Patients With ICC and Other Advanced Solid Tumors Ended
  2024-512622-29-00 7 2021-09-10 Cholangiocarcinoma (CCA) and Other Advanced Solid Tumors
• This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors) Ended
  2024-511503-41-00 3 2021-08-13 Advanced or metastatic solid tumors
• A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Local … Ended
  2024-513870-23-00 5 2021-06-28 Locally Advanced or Metastatic Unresectable Urothelial Cancer
• This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of tildacerfont to reduce glucocorticoid use … Ended
  2023-503771-13-00 4 2021-01-28 Classic Congenital Adrenal Hyperplasia
• This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that will evaluate the efficacy and safety of … Ended
  2023-503770-21-00 4 2021-01-05 Classic Congenital Adrenal Hyperplasia

Showing 337–360 of 382 trials